X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs GSK PHARMA - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD GSK PHARMA LUPIN LTD/
GSK PHARMA
 
P/E (TTM) x 26.4 67.4 39.2% View Chart
P/BV x 2.8 13.6 20.4% View Chart
Dividend Yield % 0.6 1.1 56.5%  

Financials

 LUPIN LTD   GSK PHARMA
EQUITY SHARE DATA
    LUPIN LTD
Mar-18
GSK PHARMA
Mar-18
LUPIN LTD/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,4652,760 53.1%   
Low Rs7272,040 35.6%   
Sales per share (Unadj.) Rs349.6339.0 103.1%  
Earnings per share (Unadj.) Rs5.641.4 13.4%  
Cash flow per share (Unadj.) Rs29.645.9 64.4%  
Dividends per share (Unadj.) Rs5.0035.00 14.3%  
Dividend yield (eoy) %0.51.5 31.3%  
Book value per share (Unadj.) Rs300.3242.9 123.6%  
Shares outstanding (eoy) m452.0884.70 533.7%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x3.17.1 44.3%   
Avg P/E ratio x197.257.9 340.3%  
P/CF ratio (eoy) x37.152.3 70.9%  
Price / Book Value ratio x3.69.9 36.9%  
Dividend payout %90.084.5 106.5%   
Avg Mkt Cap Rs m495,502203,280 243.8%   
No. of employees `00017.0NA-   
Total wages/salary Rs m28,6475,234 547.3%   
Avg. sales/employee Rs Th9,273.6NM-  
Avg. wages/employee Rs Th1,681.0NM-  
Avg. net profit/employee Rs Th147.4NM-  
INCOME DATA
Net Sales Rs m158,04228,715 550.4%  
Other income Rs m1,504545 275.7%   
Total revenues Rs m159,54529,260 545.3%   
Gross profit Rs m31,4755,059 622.2%  
Depreciation Rs m10,859380 2,857.6%   
Interest Rs m2,0442 102,175.0%   
Profit before tax Rs m20,0765,222 384.5%   
Minority Interest Rs m-710-   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,644178 -8,226.7%   
Tax Rs m2,8851,892 152.5%   
Profit after tax Rs m2,5133,508 71.6%  
Gross profit margin %19.917.6 113.0%  
Effective tax rate %14.436.2 39.7%   
Net profit margin %1.612.2 13.0%  
BALANCE SHEET DATA
Current assets Rs m122,09521,815 559.7%   
Current liabilities Rs m50,95615,999 318.5%   
Net working cap to sales %45.020.3 222.2%  
Current ratio x2.41.4 175.7%  
Inventory Days Days8564 133.0%  
Debtors Days Days12019 641.7%  
Net fixed assets Rs m129,87612,475 1,041.1%   
Share capital Rs m904847 106.8%   
"Free" reserves Rs m134,86619,726 683.7%   
Net worth Rs m135,77120,573 659.9%   
Long term debt Rs m64,2456 1,070,750.0%   
Total assets Rs m263,05439,475 666.4%  
Interest coverage x10.82,612.0 0.4%   
Debt to equity ratio x0.50 162,250.5%  
Sales to assets ratio x0.60.7 82.6%   
Return on assets %1.78.9 19.5%  
Return on equity %1.917.1 10.9%  
Return on capital %3.726.2 14.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53,141564 9,422.2%   
Fx outflow Rs m19,3357,429 260.3%   
Net fx Rs m33,807-6,865 -492.4%   
CASH FLOW
From Operations Rs m17,5124,728 370.4%  
From Investments Rs m-14,073-1,042 1,350.7%  
From Financial Activity Rs m-14,921-3,066 486.6%  
Net Cashflow Rs m-11,482620 -1,852.8%  

Share Holding

Indian Promoters % 46.6 0.0 -  
Foreign collaborators % 0.2 50.7 0.4%  
Indian inst/Mut Fund % 11.3 10.2 110.8%  
FIIs % 31.9 23.8 134.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 15.4 65.6%  
Shareholders   98,259 102,036 96.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   WOCKHARDT LTD.  J.B.CHEMICALS  ORCHID PHARMA LTD  BIOCON LTD  FULFORD INDIA  

Compare LUPIN LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Aug 14, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD - SHASUN PHARMA COMPARISON

COMPARE LUPIN LTD WITH

MARKET STATS